<DOC>
	<DOCNO>NCT00035867</DOCNO>
	<brief_summary>The purpose study determine safety efficacy TLK199 patient myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Study TLK199 HCl Liposomes Injection Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis MDS Adequate liver kidney function Ineligible , refusing , allogeneic bone marrow transplant At least 18 year age Discontinuation growth factor ( e.g. , G CSF ) least 2 week prior study entry Failure recover prior surgery , major surgery within 4 week study entry Pregnant lactate woman History allergy egg Other investigational drug within 14 day study entry Chemotherapy , radiotherapy immunotherapy within 14 day study entry Concomitant steroids hormone treatment neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>